Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Spexis AG432 participants30 May 2019 to 19 Oct 2021
Metastatic Breast Cancer · Locally Recurrent Breast Cancer
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Balixafortide | Natural peptide Thymulin (serum thymic factor) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Natural peptide | |
| Area | Immune and antimicrobial | Immune and antimicrobial | |
| Evidence | |||
| Amount of evidence | 20 | 625 (plus 47 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 1 (1 in people) | 17 (2 in people) | |
| Status | |||
| Approval | Not recorded | ||
| Sport (WADA) | |||
| Registered trials | 8 · 1 active1 more mentions it but does not test it | None registered | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 21 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Balixafortide | Thymulin (serum thymic factor) |
|---|---|---|
| Immune responseImmune and inflammation | 972 | 2749157 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
| Receptor activity and mechanismPharmacology | 11 | 873057 |
|---|
| Tumor growthCancer | 33 | 1717 |
|---|
| MortalityCancer | 11 | 1414 |
|---|
| Bone and jointMusculoskeletal | 22 | 624 |
|---|
| Adverse eventsWhole body | 11 | 321 |
|---|
| Heart functionCardiovascular | 22 | 22 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Balixafortide | Thymulin (serum thymic factor) |
|---|---|---|
| Bone and jointMusculoskeletalCompared as: value in the arm that got the peptide, in % | No randomized trial result 2 results from other study designs. | 56% Clinical improvement · nonathymulin 5 mg Placebo: 17% Dose studied: 5 mg/dayn not reported1987 |
No randomized trial result
2 results from other study designs.
56%
Clinical improvement · nonathymulin 5 mg
Placebo: 17%
Dose studied: 5 mg/dayn not reported1987
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 8 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 stopped early · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Spexis AG432 participants30 May 2019 to 19 Oct 2021
Metastatic Breast Cancer · Locally Recurrent Breast Cancer
Polyphor Ltd.120 participantsJul 2013 to Jun 2016
Large Reperfused ST-Elevation Myocardial Infarction
Polyphor Ltd.38 participantsApr 2012 to Dec 2015
Acute Myeloid Leukemia in Remission · Adult Acute Lymphoblastic Leukemia in Remission · Chronic Myelogenous Leukemia (CML) · Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease (HD) in 2nd or Greater Complete Remission, Partial Remission · Chronic Lymphocytic Leukemia (CLL) · Multiple Myeloma (MM) · Myelodysplastic Syndrome (MDS) · Myeloproliferative Disorders
1 more mentions it but does not test it. They only measure it or name it in their text.
No registered trial that tests Thymulin (serum thymic factor) found in ClinicalTrials.gov.